Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. - Wikidata - wikimedia - TriplyDB

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

http://www.wikidata.org/entity/Q46879650

about

Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance.MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease.Analysis of the oncogene BRAF mutation and the correlation of the expression of wild-type BRAF and CREB1 in endometriosis.Expression and function of nuclear receptor coactivator 4 isoforms in transformed endometriotic and malignant ovarian cells.Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma.Mitochondrial Genome Mutations Associated with Myocardial Infarction.Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis

P2860

Q28273722-863CFAE4-7D45-4F8F-ABFC-1EA8D3FCA973 Q33734760-5EE0C5C3-F696-470F-8BA6-CB015661FA60 Q35545814-0700DEC1-68D6-427C-951D-2CB6625D9E70 Q38654299-A6036ED2-B55D-4225-8562-7DAF0792F0E3 Q38814833-AC34F1C5-7D54-4222-803B-2255E55F113D Q40765757-F6918FF4-7F24-4948-B8E7-DD3CA383FDD5 Q41777292-4D8B7022-B3E0-4964-8FA2-C8B495A0A0ED Q47246686-F0BCD9E9-F579-4CAA-85D8-47E229C0CD20 Q50052852-03E08FD2-8042-4DB8-8007-92F3D750052D Q52717288-8728AE69-CEFE-4709-9ACC-5C90A88B95C7 Q55025572-06AD4739-2D56-43C1-9E7E-1DBE8049DDA7 Q58129865-C45D708A-A492-4250-8E4F-FA52184BB171

P2860

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

http://www.wikidata.org/entity/Q46879650

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

@en

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

@nl

type

label

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

@en

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

@nl

prefLabel

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

@en

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

@nl

P1433

Q46879650-3BB91FE4-E7B4-40B3-8969-859B255A7D06

P1476

Q46879650-A4014FD6-36B5-4618-A83B-A15D71C7AAE0

P2093

Q46879650-15FB037E-1780-4BF3-9EE9-F7085EE7F20F

Q46879650-1E513F7D-1069-45E7-A831-6EE457C8889F

Q46879650-25616179-E374-4EFF-B17A-0DF8B8C03CCE

Q46879650-5EF3B6BE-D9FD-4ECF-8C95-C54EC0E3625E

Q46879650-CF448B66-F5B6-4B72-BE06-849DF53DC47D

Q46879650-D41148A2-93E9-4E25-A563-2CB516BEF853

Q46879650-E180B3D7-F9B0-4465-89CF-545C85CFA1C4

P2860

Q46879650-07FBC32C-055F-4951-9196-FB7A762BA328

Q46879650-088CBF32-A0CB-4D42-AE8E-BFBAF9E520AD

Q46879650-1FDC1C45-FED7-4A6D-8A43-ED228EFCE95A

Q46879650-21BA7761-9739-45AA-9570-91871242AC68

Q46879650-294D6C82-8C8C-431E-9D68-D02AA6B18653

Q46879650-29AACE0B-CC18-4E34-8605-D745C9391732

Q46879650-2BF9EB71-7E07-4289-9A7B-DDF4BDAD84AA

Q46879650-2D13A5EB-BCC0-40A3-BA7E-1B3AC1D235E3

Q46879650-39F67190-6704-4048-9482-4E40AAC69EA3

Q46879650-3DE1E516-C519-4366-B7E6-B57F579BE43E

P2888

Q46879650-3F1D0FA4-D604-40D1-89D4-BCDD949F4BE9

P304

Q46879650-103BD47F-5F1E-4490-99FC-B70CAC19CF57

P31

Q46879650-298FC499-EF70-4E98-9593-D7B14E2EEFC7

P356

Q46879650-FA388484-7AE0-4A96-B2C4-F332E9EAFA66

P433

Q46879650-DF4C7270-5429-4F22-95B8-D36E883DCDF1

P478

Q46879650-9C6AF1CB-C589-4A86-BAE6-51BBBEF9B69D

P50

Q46879650-550EC7EF-FF7E-49A0-8DA1-E6A9D026DC00

P577

Q46879650-6F3EC2D4-471A-4AE6-A790-8BFB714BD2CC

P5875

Q46879650-013F6388-C756-42AE-8034-BDCF53F69318

P698

Q46879650-9B1E7299-C70C-4253-8AF8-8173F3B7C7FC

P356

S00428-014-1599-1

P1433

Virchows Archiv

P1476

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma

@en

P2093

Angela Pettinato

http://www.w3.org/2001/XMLSchema#string

Gaia Chiarello

http://www.w3.org/2001/XMLSchema#string

Gian Franco Zannoni

http://www.w3.org/2001/XMLSchema#string

Giovanni Scambia

http://www.w3.org/2001/XMLSchema#string

Giuseppina Improta

http://www.w3.org/2001/XMLSchema#string

Marco Petrillo

http://www.w3.org/2001/XMLSchema#string

Paolo Scollo

http://www.w3.org/2001/XMLSchema#string

P2860

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Targeting RAS signalling pathways in cancer therapy

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies

Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability.

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants

P2888

s00428-014-1599-1

P304

193-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00428-014-1599-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

465

http://www.w3.org/2001/XMLSchema#string

P50

Filippo Fraggetta

P577

2014-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262771158

http://www.w3.org/2001/XMLSchema#string

P698

24889043

http://www.w3.org/2001/XMLSchema#string